Journal article
Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration
The Journal of infectious diseases, v 207(2), pp 213-222
26 Oct 2012
PMID: 23105144
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background.
Antiretroviral therapy (ART)–mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication.
Methods.
A total of 23 HIV type 1 (HIV-1)–infected, virologically suppressed subjects receiving ART (CD4
+
T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg–interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed.
Results.
At week 12 of Peg–interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A,
P
= .0088; arm B,
P
= .0010; combined arms,
P
< .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A,
P
= .0046; arm B,
P
= .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (
P
= .0313) but increased residual viral loads (
P
= .0078), compared with subjects who experienced end-point failure.
Conclusions.
Peg–interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication.
Clinical Trials Registration.
NCT00594880.
Metrics
Details
- Title
- Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration
- Creators
- Livio Azzoni - The Wistar InstituteAndrea S. Foulkes - University of Massachusetts AmherstEmmanouil Papasavvas - The Wistar InstituteAngela M. Mexas - Emory University HospitalKenneth M. Lynn - The Wistar InstituteKaram Mounzer - Philadelphia FightPablo Tebas - University of PennsylvaniaJeffrey M. Jacobson - Drexel UniversityIan Frank - University of PennsylvaniaMichael P. Busch - Systems Research InstituteSteven G. Deeks - University of California, San FranciscoMary Carrington - Ragon Institute of MGH, MIT and HarvardUna O'Doherty - Emory University HospitalJay Kostman - University of PennsylvaniaLuis J. Montaner - The Wistar Institute
- Publication Details
- The Journal of infectious diseases, v 207(2), pp 213-222
- Series
- Editor's choice
- Publisher
- Oxford University Press
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000312886400006
- Scopus ID
- 2-s2.0-84871797372
- Other Identifier
- 991019335232504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Microbiology